User login
Key clinical point: Atezolizumab plus bevacizumab (Atez/Bev) shows potent therapeutic efficacy against unresectable hepatocellular carcinoma (uHCC) in patients with a good hepatic function, classified as Child-Pugh A (CP-A), but has decreased efficacy in those with CP-B.
Major finding: Patients with CP-A vs. CP-B showed better 6-, 12-, and 18-month progression-free (58.2%, 36.1%, and 27.8% vs. 49.6%, 8.7%, and non-estimable, respectively; P < .001) and overall (89.9%, 71.7%, and 51.4% vs. 63.6%, 18.4%, and non-estimable, respectively; P < .001) survival rates.
Study details: This retrospective study included 457 patients with uHCC and CP-A (n = 427) or CP-B (n = 30) who received Atez/Bev.
Disclosures: This study received no financial support. Some authors declared serving as advisors for and receiving lecture fees or research funds from various sources. Two authors declared serving as editors/editorial board members of Liver Cancer.
Source: Tanaka T et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022 (May 28). Doi: 10.1111/hepr.13797
Key clinical point: Atezolizumab plus bevacizumab (Atez/Bev) shows potent therapeutic efficacy against unresectable hepatocellular carcinoma (uHCC) in patients with a good hepatic function, classified as Child-Pugh A (CP-A), but has decreased efficacy in those with CP-B.
Major finding: Patients with CP-A vs. CP-B showed better 6-, 12-, and 18-month progression-free (58.2%, 36.1%, and 27.8% vs. 49.6%, 8.7%, and non-estimable, respectively; P < .001) and overall (89.9%, 71.7%, and 51.4% vs. 63.6%, 18.4%, and non-estimable, respectively; P < .001) survival rates.
Study details: This retrospective study included 457 patients with uHCC and CP-A (n = 427) or CP-B (n = 30) who received Atez/Bev.
Disclosures: This study received no financial support. Some authors declared serving as advisors for and receiving lecture fees or research funds from various sources. Two authors declared serving as editors/editorial board members of Liver Cancer.
Source: Tanaka T et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022 (May 28). Doi: 10.1111/hepr.13797
Key clinical point: Atezolizumab plus bevacizumab (Atez/Bev) shows potent therapeutic efficacy against unresectable hepatocellular carcinoma (uHCC) in patients with a good hepatic function, classified as Child-Pugh A (CP-A), but has decreased efficacy in those with CP-B.
Major finding: Patients with CP-A vs. CP-B showed better 6-, 12-, and 18-month progression-free (58.2%, 36.1%, and 27.8% vs. 49.6%, 8.7%, and non-estimable, respectively; P < .001) and overall (89.9%, 71.7%, and 51.4% vs. 63.6%, 18.4%, and non-estimable, respectively; P < .001) survival rates.
Study details: This retrospective study included 457 patients with uHCC and CP-A (n = 427) or CP-B (n = 30) who received Atez/Bev.
Disclosures: This study received no financial support. Some authors declared serving as advisors for and receiving lecture fees or research funds from various sources. Two authors declared serving as editors/editorial board members of Liver Cancer.
Source: Tanaka T et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022 (May 28). Doi: 10.1111/hepr.13797